Investigational Study Drug in Participants with Early Parkinson’s Disease

Study Overview

Parkinson’s disease is a brain disorder that gets worse over time. New research shows that inflammation in the brain plays an important role in how Parkinson’s disease starts and gets worse. This trial is studying an investigational study drug that may help slow the worsening of Parkinson’s Disease. We are currently enrolling people who have Parkinson's disease with symptoms beginning within the last two years.

Are you eligible to participate?

Participants Must:

  • Be 40-85 years of age

  • Have a documented diagnosis of Parkinson’s disease with symptoms that started within the past 2 years

Participants Must Not:

  • Currently take medications for Parkinson’s disease

  • Have a medical history of a movement disorder other than Parkinson’s disease

  • Be a current smoker or have smoked within the last 6 months

Study Drug Details

The investigational study drug is being studied for Parkinson's disease.  The study drug is considered an investigational treatment because it is not yet approved by the U.S. Food and Drug Administration (FDA).  It may block a specific pathway in your brain to lower the inflammation.  This may help slow down how fast Parkinson’s disease gets worse.

The investigational study drug is an oral tablet taken once per day.  You might receive the study drug or a placebo, which looks identical to the study drug but contains no actual study drug.

Study Details

  1. Screening Phase

    The screening phase lasts up to 8 weeks.  During this time, we will perform tests and exams to make sure you are eligible to participate in the study.  There may be multiple visits needed to complete all of the screening tests and procedures.

  2. Double-Blind Study Phase

    This phase is 48 weeks long and includes 10 study visits.  You will receive either active study medication or placebo during this time.

  3. Follow-Up Phase

    This phase is 4 weeks long with one study visit that occurs 4 weeks after your last visit in the double-blind phase

There may be visits which the study doctor schedules, in addition to those above.

Interested in Participating?

If you are interested in participating, please fill out the form below, and our clinical research team will reach out to you as soon as possible. We will not sell this information or use it for any purpose other than contacting you about this study.

You can also contact us by phone at (475) 318-8250.